<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123954</url>
  </required_header>
  <id_info>
    <org_study_id>V71_21</org_study_id>
    <nct_id>NCT01123954</nct_id>
  </id_info>
  <brief_title>Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers</brief_title>
  <official_title>Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study will evaluate the safety in healthy people aged 1- 45 years (male and
      female) after single intramuscular (IM) dose of trivalent subunit inactivated influenza
      vaccine till the 30-days follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Using the single vaccination for volunteers and follow up within 30 days since the first vaccination to evaluate levels of safety (AEs) after vaccination</measure>
    <time_frame>30 days, including the follow-up period</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal flu vaccine</intervention_name>
    <description>This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy people with aged 1 to 45 years;

          2. Previous history of not being vaccinated by any flu vaccines;

          3. Women of childbearing potential agree to apply the contraceptive measures during the
             study period;

          4. Do not have any acute or chronic diseases by screening;

          5. Having the abilities of understanding and conforming the study plan;

          6. Volunteer to the study;

          7. Agree to vaccinate completely and conform the follow up procedure within 30 days after
             the first vaccination.

        Exclusion Criteria:

          1. Having the suspected symptoms of infecting flu: cough, sore throat, stuffy or running
             nose, headache, malaise, myalgia and arthralgia, weakness, chilly or sweat;

          2. A prior history of allergy to any components of candidate vaccine;

          3. Sensitive to eggs or chicken protein, kanamycin, neomycin sulphate, formaldehyde,
             cetyltrimethylammonium bromide (CTAB) and polysorbate 80;

          4. Females who are pregnant or nursing (breastfeeding) mothers, or females of
             childbearing potential who are sexually active and have not used or do not plan to use
             acceptable birth control measures during the first 3 weeks after vaccination;

          5. Being immuno deficiency due to treatment;

          6. Using immunosuppressive drugs (belong to steroid group) within 06 months before
             vaccination;

          7. Being sickness or cancer or HIV (+);

          8. Participating in other study on drug or vaccination;

          9. Receipt of other vaccine within 04 weeks before participating in the study;

         10. Congenital malformation, mental disorder or members of family having the mental
             disorder;

         11. Using immune globulin or blood products within 03 months before vaccination;

         12. Having an acute or chronic diseases that can cause influence on the safety including:
             hepatic, renal, mental diseases or diabetes and transplantation;

         13. Body temperature over 37.5 degree Celcius within 01 week before vaccination;

         14. History of alcohol or drugs addicted within 05 years;

         15. Planning to travel away from the study site among the visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of examination and vaccination - Institute Pasteur of Ho Chi Minh City (LAM: Laboratoires d'Analysis Medicale)</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>December 13, 2011</last_update_submitted>
  <last_update_submitted_qc>December 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seasonal influenza</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

